Baiji Shenzhou / Anjin cooperation "injection with perintomo double resistance" was approved for listing

Blinatumomab, developed by Amgen based on its advanced dual-specific T-cell bridging system (BiTE), is the first dual-specific antibody product to be developed by Amgen's BiTE technology platform and activates the immune system to identify and kill tumor cells by presenting CD19 proteins on tumor cells to CD3 proteins specifically expressed by T-cells.
has been approved abroad for the treatment of relapsed/resoicable B-cell precursor acute lymphoblastic leukemia (ALL).
sales have risen steadily since 2016, reaching $312 million globally in 2019, according to the company's Annual Sales Data.
January this year, Baiji Shenzhou and Amjin reached a global cancer strategy, in which Baiji Shenzhou will be responsible for Amjin in China has been approved or declared three tumor drugs Angarve ® (XGEVA®) The commercialization and development of plerintomo dual anti-injection drugs in China with suminine anti-injection, KYPROLIS®infusional kafezome and BLINCYTO®
Angarve® has been approved in China, the third quarter of this year in China product revenue of $3.05 million, which is also the first commercially listed by Baiji Shenzhou Anjin products;
a while ago, Baiji three-quarter report said that it is currently in preparation for the upcoming approval of the product commercial listing work.
has been approved for sale worldwide in two dual-resistance models, Blinatumomab and Roche's Emicizumab.
catumaxomab, the world's first dual-specific antibody previously approved for sale, was de-listed and discontinued in 2017 due to commercial unsuccessfulness.
's Emmys were approved as early as November 30, 2018 for the treatment of the rare disease type A haemophilia, according to the Company's Insight database.
the two dual anti-domestic models sold worldwide have been approved after the import of the Ajin Perintomo double resistance was approved.
。